Quentin M Anstee Selected Research

selonsertib

1/2022	Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR Trials.
1/2022	Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis.
1/2020	Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
11/2019	Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis.
11/2019	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Quentin M Anstee Research Topics

Disease

64	Non-alcoholic Fatty Liver Disease 12/2022 - 07/2011
45	Fibrosis (Cirrhosis) 12/2022 - 02/2009
16	Liver Cirrhosis (Hepatic Cirrhosis) 05/2022 - 09/2012
16	Alcoholic Fatty Liver 05/2022 - 09/2010
13	Inflammation (Inflammations) 01/2022 - 02/2009
12	Liver Diseases (Liver Disease) 01/2022 - 11/2012
11	Fatty Liver 12/2022 - 09/2010
6	Hepatocellular Carcinoma (Hepatoma) 01/2021 - 08/2017
5	Insulin Resistance 01/2018 - 01/2013
4	Weight Loss (Weight Reduction) 01/2020 - 10/2013
3	Obesity 01/2022 - 01/2013
3	Pruritus (Itching) 01/2022 - 12/2019
3	Type 2 Diabetes Mellitus (MODY) 12/2020 - 02/2012
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 04/2013
2	Disease Progression 12/2021 - 01/2021
2	Weight Gain 10/2021 - 01/2016
2	Alcoholic Liver Diseases (Alcoholic Liver Disease) 01/2017 - 06/2016
2	Chronic Hepatitis C 09/2011 - 02/2009
2	Protein C Deficiency 09/2011 - 02/2009
1	Chronic Disease (Chronic Diseases) 01/2022
1	Portal Hypertension 01/2022
1	Nausea 10/2021
1	Edema (Dropsy) 10/2021
1	Diarrhea 10/2021
1	Anemia 10/2021
1	Carcinogenesis 01/2021
1	Fatigue 11/2020
1	Lung Diseases (Lung Disease) 01/2020
1	Hypertension (High Blood Pressure) 01/2020
1	Cicatrix (Scar) 01/2020

Drug/Important Bio-Agent (IBA)

22	Biomarkers (Surrogate Marker)IBA 12/2022 - 10/2013
12	LipidsIBA 05/2022 - 01/2013
8	EnzymesIBA 10/2022 - 01/2013
8	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2013
7	Triglycerides (Triacylglycerol)IBA 01/2020 - 06/2014
5	Proteins (Proteins, Gene)FDA Link 10/2022 - 06/2016
5	nasIBA 10/2022 - 05/2012
5	selonsertibIBA 01/2022 - 11/2019
5	obeticholic acidIBA 01/2022 - 05/2015
4	CollagenIBA 01/2022 - 01/2015
4	Alanine Transaminase (SGPT)IBA 01/2022 - 06/2013
4	Aspartate Aminotransferases (Aspartate Transaminase)IBA 11/2021 - 06/2013
3	Phospholipases (Phospholipase)IBA 10/2022 - 06/2016
3	RNA (Ribonucleic Acid)IBA 11/2021 - 01/2018
3	Insulin (Novolin)FDA Link 01/2021 - 01/2013
3	CytokinesIBA 01/2018 - 01/2017
2	MicroRNAs (MicroRNA)IBA 02/2022 - 01/2022
2	Syntex adjuvant formulationIBA 02/2022 - 10/2021
2	Oxidoreductases (Dehydrogenase)IBA 01/2022 - 02/2015
2	Pharmaceutical PreparationsIBA 01/2022 - 10/2021
2	Complement C3 (C3 Complement)IBA 12/2021 - 09/2019
2	Peptides (Polypeptides)IBA 10/2021 - 01/2020
2	cenicrivirocIBA 01/2020 - 01/2020
2	HDL LipoproteinsIBA 01/2020 - 01/2019
2	Thrombin FDA Link 05/2018 - 02/2009
2	Immunoglobulin A (IgA)IBA 11/2017 - 05/2014
2	DNA (Deoxyribonucleic Acid)IBA 01/2017 - 01/2015
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2016 - 09/2012
2	Blood Glucose (Blood Sugar)IBA 01/2016 - 03/2015
2	CreatinineIBA 01/2016 - 03/2015
2	Histones (Histone)IBA 01/2013 - 09/2012
2	ChromatinIBA 01/2013 - 09/2012
2	Fatty Acids (Saturated Fatty Acids)IBA 02/2012 - 11/2010
2	FibrinIBA 09/2011 - 02/2009
2	Fibrinogen (Factor I)FDA Link 09/2011 - 02/2009
2	factor V LeidenIBA 09/2011 - 02/2009
2	Factor VIII (Coagulation Factor VIII)IBA 09/2011 - 02/2009
1	very low density lipoprotein triglycerideIBA 10/2022
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 02/2022
1	Scavenger Receptors (Scavenger Receptor)IBA 01/2022
1	SugarsIBA 01/2022
1	amidoximeIBA 01/2022
1	simtuzumabIBA 01/2022
1	clonidine-displacing substance (ClDS)IBA 01/2022
1	Antiviral Agents (Antivirals)IBA 01/2022
1	Monoclonal AntibodiesIBA 01/2022
1	O(4)-methylthymidine triphosphateIBA 01/2022
1	Hyaluronic Acid (Hyaluronan)IBA 11/2021
1	thrombospondin 2IBA 11/2021
1	Glycoproteins (Glycoprotein)IBA 11/2021
1	lanifibranorIBA 10/2021
1	Peptide Hydrolases (Proteases)FDA Link 10/2021
1	micaIBA 03/2021
1	Bevacizumab (Avastin)FDA Link 01/2021
1	atezolizumabIBA 01/2021
1	Serum AlbuminIBA 11/2020
1	ChemokinesIBA 01/2020
1	Bone Morphogenetic Proteins (Bone Morphogenetic Protein)IBA 01/2020
1	Keratin-18 (Keratin 18)IBA 01/2020
1	tropifexorIBA 01/2020
1	Antinuclear AntibodiesIBA 01/2020
1	MAP Kinase Kinase Kinase 5IBA 01/2020
1	EpitopesIBA 09/2019
1	HDL CholesterolIBA 01/2019

Therapy/Procedure

16	Therapeutics 12/2022 - 11/2012
4	Liver Transplantation 01/2020 - 07/2011
3	Drug Therapy (Chemotherapy) 12/2022 - 05/2015
2	Transplantation 10/2019 - 10/2019
1	Aftercare (After-Treatment) 01/2022
1	Caloric Restriction 01/2020